Cost Curve
everything drug pricing and policy, every day
Se connecter
And PBM news is back with a vengeance
Plus some math from the former head of the CBO helps estimate how much tax revenue is being lost because of out-of-control 340B growth
And Lilly joins J&J in taking legal actions to move to a more accountable 340B system
It's a blow to public health, and it suggests we're going to have to think and talk about drug value in new ways, to new audiences
And a good answer to the 'why does the U.S. pay more?' question from AEI's Kirsten Axelsen
And the JNJ 340B suit got picked up all over the place. Encouraging!
And I took a deep dive into the shallow pool that is Project 2025's recommendations on drug pricing
And a reminder that this will be a big week for 340B news, for those paying attention
Just a reminder: no one knows anything
It's a brief one today, with a bit on the California 340B measure but not much else
It's Election Day. Please vote. And then you should probably unplug. Maybe watch some hockey. That's my plan, anyway.
And a new analysis finds that even it were legal to use Bayh-Dole march-in rights to control drug prices (and it's almost certainly not), there aren't even that many drugs that would qualify
